Back to search

Article

Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 Study

2026-02-27

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Bireociclib, a novel cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, has demonstrated efficacy in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. This exploratory analysis aimed to identify biomarkers of response and resistance to bireociclib through dynamic circulating tumor DNA (ctDNA) prof...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
561b54e9-ea5b-5f1e-8dfa-556651247d8a
DOI
10.21203/rs.3.rs-8242447/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 StudyDOI 10.21203/rs.3.rs-8242447/v1
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.Semantic proximity
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.Semantic proximity
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.Semantic proximity
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Semantic proximity
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.Semantic proximity
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.Semantic proximity
Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.Semantic proximity
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerSemantic proximity
The Multi-Omic Transformation of Breast Cancer Diagnostics: A Comprehensive Review of the Transition from Immunohistochemistry to Liquid Biopsy and Next-Generation SequencingSemantic proximity
Select a neighboring publication to make it the new centre.